MedPath

Rosehip Powder for Knee Osteoarthritis

Phase 2
Completed
Conditions
Osteoarthritis
Interventions
Dietary Supplement: Rosehip powder
Registration Number
NCT01430481
Lead Sponsor
Frederiksberg University Hospital
Brief Summary

The aim of this study is to compare three combinations of preparations in a comparative trial program on rosehip powder for knee OA. The trial is a comparative, 12-week, randomized, double-blind, active-controlled trial, designed to determine the comparative efficacy and safety of these preparations in patients with pain from knee OA.

Detailed Description

Complementary or alternative therapies (incl. nutraceuticals - functional ingredients sold as powders, pills, and other medicinal forms not generally associated with food) for OA are commonly used, and it is therefore important that health care providers are aware of the evidence supporting the claims. One proposed nutraceutical which has shown promising results in OA patients, is the hip powder of Rosa canina.

The findings from a previous meta-analysis of rosehip powder from Rosa canina for symptomatic treatment of OA was a small but potentially relevant reduction of pain and a statistically significant reduction in use of analgesics.

The present study is undertaken to compare two different products, one of which is tested in two different doses, in a non-inferiority design.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
150
Inclusion Criteria
  • 40 years of age and have clinical evidence (diagnosed according to the American College of Rheumatology [ACR] criteria) and radiographic evidence of OA.
  • Eligible patients have a self-reported pain level corresponding to at least 40 mm on a 100 mm VAS when screened
Exclusion Criteria
  • Patients will not be considered eligible if they are considered morbidly obese -having a body mass index (BMI) above 40 kg/m2, concurrent medical or arthritic conditions that could confound evaluation of the index joint, or coexisting disease that could preclude successful completion of the trial.
  • Patients who already take a rosehip powder as a dietary supplement; have inability to speak Danish fluently; or have a mental state impeding compliance with the program will not be considered eligible for inclusion.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
New rosehip formulation (B)Rosehip powder6 capsules of modified hip powder of Rosa canina made from the seeds and husks of the fruits from a subtype of R. canina hip powder (i.e., rosehip)
Standard Rosehip Powder (A)Rosehip powder6 capsules of standardized hip powder of Rosa canina made from the seeds and husks of the fruits from a subtype of R. canina hip powder (i.e., rosehip)
New rosehip formulation in half dose (C)Rosehip powder3 capsules of modified hip powder of Rosa canina made from the seeds and husks of the fruits from a subtype of R. canina hip powder (i.e., rosehip)
Primary Outcome Measures
NameTimeMethod
Pain, Walking on flat surface - range: 0-100week 12

Knee injury and Osteoarthritis Outcome Score (KOOS) subscale item

Secondary Outcome Measures
NameTimeMethod
Pain - range: 0-100week 12

KOOS

Symptoms - range: 0-100week 12

KOOS

VAS Disability - 0-100week 12

VAS

VAS patient global assessment of disease status - 0-100week 12

VAS

VAS physician global assessment of disease status - 0-100week 12

VAS

Physical component summary - range: 0-100week 12

Short-Form-36 score

Mental component summary - range: 0-100week 12

Short-Form-36 score

Function in daily living - range: 0-100week 12

KOOS

Knee related Quality of life - range: 0-100week 12

KOOS

VAS Pain - 0-100week 12

VAS

Trial Locations

Locations (1)

The Parker Institute, Frederiksberg Hospital

🇩🇰

Frederiksberg, Denmark

© Copyright 2025. All Rights Reserved by MedPath